Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s new untreated follicular lymphoma therapy backed by NICE

Roche’s new untreated follicular lymphoma therapy backed by NICE

13th February 2018

The National Institute for Health and Care Excellence (NICE) has given the green light to Roche's new untreated follicular lymphoma therapy.

NICE had originally concluded that Gazyvaro was too expensive for NHS use, but has reconsidered its decision after Roche submitted a revised economic analysis.

The organisation's appraisal committee was sufficiently confident that Gazyvaro was a good therapy option for adults with untreated advanced follicular lymphoma if the patient had a Follicular Lymphoma International Prognostic Index score of at least two – and if Roche provided the drug with the discount agreed in the patient access scheme.

NICE's decision has been hailed by blood cancer research charity Bloodwise, which said it is good news both for patients and their families.

Dr Alasdair Rankin, director of research at the charity, commented: "Around 2,000 people will be diagnosed with follicular lymphoma each year in the UK. 

"While not everyone will need to start treatment immediately, the knowledge that doctors will have the most effective and appropriate treatment options available when they do is really important to patients.”

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.